Free Trial
→ Two Unmistakable Patterns Return… (From Golden Portfolio) (Ad)
NASDAQ:GYRE

Gyre Therapeutics 5/15/2023 Earnings Report

Gyre Therapeutics logo
$8.40 +0.68 (+8.81%)
Closing price 04/15/2025 04:00 PM Eastern
Extended Trading
$6.11 -2.29 (-27.25%)
As of 04:32 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Earnings HistoryForecast

Gyre Therapeutics EPS Results

Actual EPS
-$1.65
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Gyre Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Gyre Therapeutics Announcement Details

Quarter
Date
5/15/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Gyre Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Friday, May 9, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Remove Ads

Gyre Therapeutics Earnings Headlines

Gyre Therapeutics announces NMPA approval for trial on pirfenidone
March 31, 2025 | markets.businessinsider.com
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
March 31, 2025 | globenewswire.com
Two Unmistakable Patterns Return…
The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at record pace. Why massive amounts of gold are being moved between countries. Why governments are repositioning their gold reserves. But here's what most people miss, the second pattern: During these resets, a unique anomaly appears in certain gold mining stocks. I call it the "Golden Anomaly."
April 16, 2025 | Golden Portfolio (Ad)
Gyre Therapeutics announces publication of protocol for Phase 3 trial on F351
March 27, 2025 | markets.businessinsider.com
We Think You Should Be Aware Of Some Concerning Factors In Gyre Therapeutics' (NASDAQ:GYRE) Earnings
March 27, 2025 | finance.yahoo.com
Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology
March 27, 2025 | globenewswire.com
See More Gyre Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Gyre Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gyre Therapeutics and other key companies, straight to your email.

About Gyre Therapeutics

Gyre Therapeutics (NASDAQ:GYRE), a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

View Gyre Therapeutics Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles